1. Isorhynchophylline exerts anticancer and anti-metastatic effects through regulation of multiple signaling cascades in hepatocellular carcinoma cells.
2. Isorhynchophylline exerts neuroprotective effect against Aβ 25-35-induced neurotoxicity in vitro via PI3K/Akt signaling pathway.
3. Isorhynchophylline shows antidepressant-like effects, which are mediated, at least in part, by the inhibition of monoamine oxidases.
4. Isorhynchophylline shows inhibition on angiotensin II-induced proliferation in rat vascular smooth muscle cells.
5. Isorhynchophylline shows anti-inflammatory effects in mouse N9 microglial cells.
6. Isorhynchophylline plays a remarkably preventive role in cardiac arrhythmias through the inhibition of calcium currents in rats and guinea pigs.
1. The hexane-ethanol extract of Glycyrrhiza uralensis, which contains licoricidin, is a potent anti-metastatic agent, which can markedly inhibit the metastatic and invasive capacity of malignant prostate cancer cells.
2. Licoricidin inhibits lung metastasis of 4T1 mammary carcinoma cells, which may be mediated via inhibition of cancer cell migration, tumor angiogenesis, and lymphangiogenesis.
3. Licoricidin and licorisoflavan A are effective in inhibiting the growth of all three bacterial species(Porphyromonas gingivalis, Prevotella intermedia and Solobacterium moorei), with minimal inhibitory concentrations in the range of 2-80 ug /ml, they have a potential for reducing bacterial volatile sulfur compounds (VSCs) production and therefore for controlling halitosis.
4. Licoricidin blocks UVA-induced photoaging via ROS scavenging,this activity converges to limit the activity of MMP-1, suggests that licoricidin may be considered as an active ingredient in new topically applied anti-ageing formulations.
5. Licoricidin and licorisoflavan A have potential for the development of novel host-modulating strategies for the treatment of cytokine and/or MMP-mediated disorders such as periodontitis.